MedTrace Logo

Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC

NCT02018757 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2014-05-28

No results posted yet for this study

Summary

The purpose of the study is to determine whether transarterial chemoembolization containing arsenic trioxide is safe and effective in the treatment of intermediate-stage hepatocellular carcinoma.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

TACE containing As2O3

transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol

DRUG

TACE containing placebo

transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • Zhongda Hospital

    collaborator OTHER

  • Fudan University

    collaborator OTHER

  • Xijing Hospital

    collaborator OTHER

  • First Hospital of China Medical University

    lead OTHER

Principal Investigators

  • Haibo Shao, MD,PhD · First Hospital of China Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02018757 on ClinicalTrials.gov